gemfibrozil has been researched along with Muscle Disorders in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We describe a case of severe myopathy and rhabdomyolysis associated with concomitant use of simvastatin and gemfibrozil." | 7.69 | Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. ( Isley, W; Rajeshawari, M; Tal, A, 1997) |
| "The Food and Drug Administration documents the receipt of 12 case reports of severe myopathy or rhabdomyolysis associated with concomitant use of lovastatin and gemfibrozil, including 10 voluntary postmarketing, and 2 required, reports." | 7.68 | Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. ( Gross, TP; Pierce, LR; Wysowski, DK, 1990) |
| " We describe a case of severe myopathy and rhabdomyolysis associated with concomitant use of simvastatin and gemfibrozil." | 3.69 | Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. ( Isley, W; Rajeshawari, M; Tal, A, 1997) |
| "The Food and Drug Administration documents the receipt of 12 case reports of severe myopathy or rhabdomyolysis associated with concomitant use of lovastatin and gemfibrozil, including 10 voluntary postmarketing, and 2 required, reports." | 3.68 | Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. ( Gross, TP; Pierce, LR; Wysowski, DK, 1990) |
| " Regardless of the fibric acid derivative chosen, an empiric dosage reduction of 20% and close INR monitoring are warranted in patients receiving warfarin." | 2.45 | Interaction between gemfibrozil and warfarin: case report and review of the literature. ( Dixon, DL; Williams, VG, 2009) |
| " The long term administration of statin and fibrate to patients with primary and secondary hyperlipidemia was considered safe on the basis of our experience and literature data." | 2.42 | [Antilipemic therapy and rhabdomyolysis]. ( Balogh, Z; Paragh, G; Romics, L, 2003) |
| " We reviewed gemfibrozil- and fenofibrate-associated adverse event reports (AERs) submitted to the US Food and Drug Administration over a 5-year period." | 1.35 | Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. ( Alsheikh-Ali, AA; Holoshitz, N; Karas, RH, 2008) |
| "A 61-year-old woman with hyperlipidemia was treated with gemfibrozil." | 1.29 | [Gemfibrozil-induced myopathy]. ( Adler, Y; Aron, A; Weiss, P, 1993) |
| "Lovastatin has been used with increasing frequency over the past few years to reduce serum cholesterol." | 1.28 | Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study. ( Chucrallah, A; De Girolami, U; Federman, M; Freeman, R, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (62.50) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Zabihi, M | 1 |
| Askarian, F | 1 |
| Hekmatimoghaddam, S | 1 |
| Zabihi, MS | 1 |
| Vahidi, F | 1 |
| Dixon, DL | 1 |
| Williams, VG | 1 |
| Paragh, G | 1 |
| Balogh, Z | 1 |
| Romics, L | 1 |
| Holoshitz, N | 1 |
| Alsheikh-Ali, AA | 1 |
| Karas, RH | 1 |
| Tobert, JA | 2 |
| Aron, A | 1 |
| Adler, Y | 1 |
| Weiss, P | 1 |
| Rosenson, RS | 1 |
| Tal, A | 1 |
| Rajeshawari, M | 1 |
| Isley, W | 1 |
| Weismantel, D | 1 |
| Danis, P | 1 |
| Chucrallah, A | 1 |
| De Girolami, U | 1 |
| Freeman, R | 1 |
| Federman, M | 1 |
| Magarian, GJ | 1 |
| Lucas, LM | 1 |
| Colley, C | 1 |
| London, SF | 1 |
| Gross, KF | 1 |
| Ringel, SP | 1 |
| Pierce, LR | 1 |
| Wysowski, DK | 1 |
| Gross, TP | 1 |
4 reviews available for gemfibrozil and Muscle Disorders
| Article | Year |
|---|---|
Interaction between gemfibrozil and warfarin: case report and review of the literature.
Topics: Anticoagulants; Atrial Fibrillation; Drug Interactions; Follow-Up Studies; Gemfibrozil; Humans; Hypo | 2009 |
[Antilipemic therapy and rhabdomyolysis].
Topics: Anticholesteremic Agents; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Gemfibrozil; Hu | 2003 |
Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?
Topics: Anticholesteremic Agents; Dose-Response Relationship, Drug; Drug Monitoring; Evidence-Based Medicine | 2001 |
Gemfibrozil-induced myopathy.
Topics: Clofibrate; Drug Therapy, Combination; Gemfibrozil; Humans; Hypertriglyceridemia; Lovastatin; Male; | 1991 |
12 other studies available for gemfibrozil and Muscle Disorders
| Article | Year |
|---|---|
Combination of atorvastatin and gemfibrozil plus physical activity: an animal model of statin/fibrate-induced myopathy.
Topics: Animals; Atorvastatin; Disease Models, Animal; Fibric Acids; Gemfibrozil; Hydroxymethylglutaryl-CoA | 2021 |
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Databases, Factual; | 2008 |
HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
Topics: Drug Combinations; Drug Interactions; Follow-Up Studies; Gemfibrozil; Humans; Lovastatin; Muscular D | 1995 |
Lovastatin and myopathy.
Topics: Drug Synergism; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1994 |
[Gemfibrozil-induced myopathy].
Topics: Diabetes Complications; Female; Gemfibrozil; Humans; Hyperlipidemias; Kidney Failure, Chronic; Middl | 1993 |
Gemfibrozil-lovastatin-associated myalgia.
Topics: Drug Therapy, Combination; Gemfibrozil; Humans; Lovastatin; Muscular Diseases | 1993 |
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; H | 1997 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study.
Topics: Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lovastatin; Microscopy, Electron; Middle Age | 1992 |
Cholesterol-lowering agent myopathy (CLAM).
Topics: Aged; Anticholesteremic Agents; Female; Gemfibrozil; Humans; Lovastatin; Muscular Diseases | 1991 |
Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil.
Topics: Adolescent; Creatine Kinase; Drug Synergism; Drug Therapy, Combination; Gemfibrozil; Humans; Isoenzy | 1990 |
Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
Topics: Acute Kidney Injury; Adult; Aged; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Fem | 1990 |